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Abstract
Recent advances in genome inspired target discovery, small molecule screens, development of biological and
nanotechnology have led to the introduction of a myriad of new differently sized agents into the clinic. The differences
in small and large molecule delivery are becoming increasingly important in combination therapies as well as the use of
drugs that modify the physiology of tumors such as anti-angiogenic treatment. The complexity of targeting has led to the
development of mathematical models to facilitate understanding, but unfortunately, these studies are often only applicable
to a particular molecule, making pharmacokinetic comparisons difficult. Here we develop and describe a framework for
categorizing primary pharmacokinetics of drugs in tumors. For modeling purposes, we define drugs not by their mechanism
of action but rather their rate-limiting step of delivery. Our simulations account for variations in perfusion, vascularization,
interstitial transport, and non-linear local binding and metabolism. Based on a comparison of the fundamental rates
determining uptake, drugs were classified into four categories depending on whether uptake is limited by blood flow,
extravasation, interstitial diffusion, or local binding and metabolism. Simulations comparing small molecule versus
macromolecular drugs show a sharp difference in distribution, which has implications for multi-drug therapies. The tissue-
level distribution differs widely in tumors for small molecules versus macromolecular biologic drugs, and this should be
considered in the design of agents and treatments. An example using antibodies in mouse xenografts illustrates the
different in vivo behavior. This type of transport analysis can be used to aid in model development, experimental data
analysis, and imaging and therapeutic agent design.
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Introduction
The pharmacokinetics (PK) of a drug or imaging agent is a
major determinant of its utility and efficacy in the clinic. Despite
its importance, poor drug distribution and overall tumoral uptake
is often neglected as a mechanism of drug resistance in cancer [1]
and becomes even more complicated in multidrug regimens [2].
Similarly, low accumulation of imaging agents often reflects poor
delivery rather than measurement of the target of interest [3,4].
The complexity of these issues results in researchers becoming
heavily dependent on animal models to test the efficacy of new
agents. However, mathematical analysis of the mechanisms
involved can provide important insight into the causes of poor
uptake and distribution. Given the limited amount of detailed
information that can be sampled in animal models and the clinic,
these models are finding increasing utility as part of drug and
imaging agent development [5,6].
In this work, we develop a generic model that minimizes the
number of suppositions about drug distribution to describe the
behavior of therapeutic and diagnostic drugs in tumor environ-
ments. We define this ‘systems’ approach as one that does not
make any assumptions about which steps are important prior to
simulating the uptake, and all the major rates are considered
simultaneously. In this manner, the rate limiting step(s) can be
unambiguously identified. The purpose of these simulations is not
to capture all the highly complex factors affecting drug distribution
in tumors but rather to serve as a starting point for identifying the
major determinants affecting the distribution of new drugs, to
focus more detailed study of pharmacokinetics of specific agents,
and to provide a logical, broad overview of the major differences
between the distribution of the different class agents. Current
pharmacokinetic models are often developed based on static
models [7] and from empiric observations based on widely
differing assumptions [8,9]. It is becoming increasingly important
to understand the interaction between agents with drastically
differing PK profiles, such as with multidrug regimens [10] and in
pretargeting strategies [11]. Many of the concepts outlined in this
model have been known for some time while others are poorly
described in the literature. What is lacking is a broad, self-
consistent theory for comparative purposes.
The modeling framework outlined in this work provides a
broadly applicable and self-consistent theoretical framework for
comparing the uptake of agents in order to better interpret results,
design new experiments, and develop more efficacious imaging
agents and therapies.
We empirically define class I agents as having uptake limited by
local tumor blood flow, class II agents having limited vessel
permeability and surface area for extravasation, class III agents
having limited interstitial diffusion in the tissue, and class IV
agents having limited local binding or metabolism of the agent.
While the interaction of drug properties and tumor physiology
cannot be completely separated, given the large range in drug
properties (e.g. 5 orders of magnitude range in permeability), the
drug properties dominate the class determination making this
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e24696analysis useful in drug design. Each of these classes exhibits unique
behavior in vivo, and often how an agent is used (systemic versus
local delivery, saturating versus subsaturating doses) will affect the
class of the agent. To further develop the modeling framework,
three instructive examples were analyzed (Figure 1A) as these
examples are well studied and span the spectrum of molecular size:
oxygen [12,13,14,15,16,17], fluorodeoxyglucose [18,19], and
monoclonal antibodies [20,21].
Materials and Methods
Mathematical simulations
Details of the mathematical model can be found in the
appendix. Briefly, a Krogh cylinder geometry was used where a
cylindrical blood vessel segment is surrounded by tissue with a
radius approximately equal to half the local inter-capillary distance
(Figure 1B). Blood flows from the arterial end, where a systemic
two-compartment model with biexponential decay defines the
concentration. The local blood concentration is determined by the
blood velocity, permeability of the vessel wall, and fraction of free
drug (not bound to blood cells or plasma proteins). Cellular uptake
in the blood was ignored (File S1) given the slower kinetics relative
to blood flow [22]. A mixed boundary condition is used at the
capillary interface, where the flux at the capillary wall determined
by the permeability is equal to the diffusive flux into the tissue. In
the tissue, the free drug undergoes radial and axial diffusion along
with agent specific reaction terms. For small molecules, this
involves cellular uptake and metabolism (e.g. oxygen utilization,
irreversible trapping over short time scales by FDG phosphory-
lation, reversible uptake for doxorubicin). For antibodies, this
involves reversible binding and dissociation with irreversible
internalization. Due to the lack of functional lymphatics in
tumors, lymphatic drainage was ignored [23]. The following
equations defined the plasma concentration, plasma tissue
interface, and tissue concentration (for first order kinetics):
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where [C]plasma is the total concentration of drug in the plasma, t is
time, v is the local blood velocity, L is the length along the vessel
segment, Rcap is the capillary radius, H is the hematocrit, P is the
vessel wall permeability, ffree is the fraction of drug that is
unbound, [C]tissue,free is the unbound concentration in the tissue
(overall/pseudohomogenous concentration), and epsilon the void
fraction. D is the effective diffusion coefficient in tissue, r is the
radial distance from a vessel, and krxn defines the local reaction
rate (which is first order in this example equation).
The method of lines was used with axial and radial variations
and solved with a stiff solver using Matlab (The Mathworks;
Natick, MA). A sparse Jacobian was defined to decrease simulation
times.
Mouse model experiments
For the mouse xenograft experiments, HT-29 and A431 cells
were purchased from ATCC (Manassas, VA) and maintained in
appropriate media. Antigen expression levels were measured
using quantitative beads (Bangs Laboratories; Fishers, IN) per the
manufacturer’s instructions. For xenograft experiments, 1.5
million cells diluted in PBS were injected subcutaneously in
anesthetized nude mice (Cox7 animal facility, Boston, MA). After
2–3 weeks when tumors were approximately 5 mm in diameter,
the mice were used for experiments. Cetuximab (ImClone
Systems Inc and Bristol-Myers Squibb; Branchburg, NJ) was
labeled with VivoTag-680 (Perkin Elmer; Waltham, MA) per the
manufacturer’s instructions. Either 30 mgo r3 0 0mg was delivered
via tail vein 3 days prior to imaging. Mice were imaged using an
OV110 small animal imager (Olympus; Center Valley, PA) using
appropriate filters for 680 nm wavelength dye. The skin covering
the tumors was removed prior to imaging to reduce scattering
and variability in depth. The fluorescence intensity of 26 tumors
was measured by region of interest analysis using ImageJ (NIH),
Figure 1. Example molecules and model structure. (A) Space filling models of oxygen, FDG, doxorubicin, and an IgG for size comparison. (B)
Diagram of a Krogh cylinder labeled with the four fundamental steps in tumor localization.
doi:10.1371/journal.pone.0024696.g001
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Jolla, CA). All animal experiments were carried out in
accordance with guidelines from the Massachusetts General
Hospital Subcommittee on Research Animal Care (Protocol
#2010N000137).
Pharmacokinetic model
Analysis of the major mechanistic steps of drug delivery in
tumors yields the possibility of four major rate-limiting steps
(four resistances in series). The first limitation is from local blood
flow (Table 1). Molecules in this class are able to easily escape
the vasculature and quickly diffuse within the tissue where they
are rapidly taken up and/or metabolized [14,24,25]. The ability
to quickly transport through the tissue actually depletes the
concentration along the length of blood vessels, which can be
compensated by increasing blood flow. Oxygen and many small
molecule drugs (e.g. doxorubicin) fall into this category given
their small size and ability to diffuse through membranes. The
second limitation is poor extravasation across the vessel walls
[20,26]. While small molecule drugs can often diffuse across
membranes, the endothelial cells lining capillaries provide a
more formidable barrier to macromolecules and nanoparticles.
These large hydrophilic agents cannot easily cross the plasma
membrane and access the interstitium by convection and/or
diffusion between endothelial cells. Normally, vessels are held
together by tight junctions, but these restrictions are slightly
relaxed in tumors due to poor vascular formation (e.g. lack of
pericyte coverage) and permeability factors (e.g. VEGF) that can
also induce fenestrations. However, even with increased
permeability relative to normal vessels, this step is often rate
limiting for macromolecules such as monoclonal antibodies. The
third limitation to drug uptake is interstitial transport. In tumors,
elevated interstitial pressure reduces convective transport [27],
making diffusion the dominant mechanism of transport (File S1).
Extensive reversible tissue binding can further reduce the
effective diffusion coefficient, increasing tissue heterogeneity
[28]. Many times this is the limiting step for local drug delivery,
such as topical delivery or intraperitoneal chemotherapy. Agents
that have direct access to the tissue avoid the blood flow and
endothelial barriers but often have long diffusion distances
within the target tissue [29,30]. Finally, the last step in
localization is the local binding and/or metabolism of the agent.
This is often the case for metabolic imaging agents or
intracellular enzyme substrates. Here, the final step in localiza-
tion is rate-limiting, so the total uptake is proportional to the
target or cellular process of interest [31].
Results
Class Validation
To test the class generalizations, numerical simulations were
carried out for sample molecules. The specific parameters used are
given in Table 2, and details of these estimates can be found in File
S1. The blood supply was fixed for all agents, but the permeability
varies by over 5 orders of magnitude. This is caused by the large
differences in molecular weight, the ability (or lack thereof) to
diffuse across the endothelial cell membrane, and the rate of
transport between endothelial cell-cell junctions. Free diffusion
coefficients through tissue are also affected by the ability to
penetrate cell membranes, the interstitial space, and molecular
size. The local binding and metabolism rates depend on the
mechanism of local immobilization. For oxygen and doxorubicin, a
saturable reaction rate was used which switches from zero order to
first order under low concentrations. The binding rate for
antibodies assumes that the interaction is high affinity and
therefore irreversible [32]. While the rate limiting step for FDG
uptake is debated [33,34], both glut1 transport and hexokinase
activity act at the local level. Since FDG competes with
endogenous glucose, the uptake rate is first order (File S1). Finally,
protease imaging agents are included as a macromolecular class IV
agent, and the local step is pinocytosis of the intracellular protease
sensor [35].
The simulations for Class I transport show significant axial
variation as the molecule is consumed in the tissue and depleted
from the blood (Figure 2A, top). These variations indicate that not
only is the distance along a vessel and blood flow rate important
for oxygen distribution, but also temporal variations have a major
effect, a class I trait. Changes in blood flow velocity or temporary
stagnation [21,36] cause transient/acute hypoxia in simulated
tissue regions (data not shown). Given the high permeability of
oxygen across a single cell layer, this does not present a significant
barrier to uptake, consistent with experimental results [16]. In
more specialized models, this resistance is often ignored. The
heterogeneous vascularization of tumors often creates regions with
few to no vessels in the tissue. Using all the same parameters
except for the intercapillary distance, a simulation shows a very
different behavior in a region with few vessels (Figure 2A, bottom).
Here there are significant radial gradients as the oxygen is
consumed before it can diffuse to the maximum radius. In this
scenario, even if blood flow could be increased without limit, the
tissue farthest from the vessel would never be oxygenated due to
the diffusive limitation (class III agent). This dependence on the
orientation of vessels requires accurate three-dimensional models
to recapitulate the in vivo scenario [15,37].
Table 1. Pharmacokinetic Classes.
Class Uptake Limitation Examples Note
I Blood Flow Oxygen, doxorubicin,
many small molecule drugs
Blood velocity and flow rate is important
II Extravasation Antibodies, nanoparticles,
many macromolecular drugs
Permeability surface area product
(PS/V) is important
III Diffusion Oxygen, local drug delivery,
highly lipophilic drugs
Spatial distribution of vessels or size of micrometastasis is
important
IV Local Binding/
Metabolism
FDG, intracellular protease sensors Local binding and/or metabolism is important
doi:10.1371/journal.pone.0024696.t001
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Class Specific Examples Blood Flow Permeability Diffusion Reaction
I Doxorubicin 0.1 mL/g/min
L=500mm
2.8 mm/s 160 mm
2/s
e=0.4 43nM=s
½C 
½C z160nM
I, III Oxygen 485 mm/s 1500 mm
2/s
e=1.0 6:0mM=s
½C O2
½C O2z3:0mM
II Antibodies 0.003 mm/s 10 mm
2/s
e=0.2
10
5/M/s
[Ag] =660 nM
IV FDG 1 mm/s 500 mm
2/s
e=0.44
5.87610
24/s
IV Protease Sensors 0.001 mm/s 10 mm
2/s
e=0.2
1.1610
25/s
Group Ratio Note Oxygen FDG Doxorubicin Antibodies
Vessel Depletion
number d:
2PffreeLKrogh
v 1{H ðÞ Rcap
~
Pffree S=V
  
Q 1{H ðÞ
Extravasation
vs. Blood Flow
14.5 3.0 2.4 0.0090
Biot number
Bi:
2PRcap
De
Extravasation
vs. Diffusion
5.2 0.073 0.7 0.024
Damkohler
number Da:
krxnR2
Krogh
De
Local Binding/
Reaction vs. Diffusion
0.13 to .2.0 * 0.015 23.4 ** 230 ***
*= dependent on local distance between vessels and plasma concentration.
**= assuming 1
st order cellular uptake.
***= assuming a highly expressed target with 10
6 binding sites per cell.
doi:10.1371/journal.pone.0024696.t002
Figure 2. Simulation results for different class agents. (A) Oxygen simulation in region with closely space vessels (50 mm Krogh radius)
showing decreasing axial concentration due to poor blood flow (top). With the Krogh radius increased to 200 mm, the radial gradients show diffusion
limited uptake for oxygen (bottom). (B) Antibody uptake is heterogeneous due to rapid binding relative to diffusion, and the lack of axial gradients
indicates blood flow is not limiting (top). An epifluorescence image of an A431 tumor xenograft slice 24 hrs after 30 mg of cetuximab-VivoTag 680
was injected intravenously shows the perivascular distribution of the antibody (bottom). (C) The blood flow, extravasation, and diffusion are faster
than cellular uptake for the class IV agent FDG resulting in homogenous distribution in the interstitium (top). This occurs even with heterogeneous
cellular uptake as demonstrated by the intracellular FDG-6-phosphate in the same simulation (bottom).
doi:10.1371/journal.pone.0024696.g002
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tumor tissue, as may be expected given their structure. Simulations
for antibody uptake show no detectable axial gradients (Figure 2B,
top). These agents are limited by the extravasation rate from the
blood, so a minimal amount exits the vessel. In isolated tumor
preparations, the miniscule drop in concentration of macromol-
ecules is within the experimental noise [9]. This makes these
agents much less susceptible to changes in blood flow, and
specialized models will often ignore differences along the length of
blood vessels [38]. The capillary wall provides a significant barrier
to uptake, so there is a large concentration difference between free
drug in the blood and unbound drug in the tissue. This large
gradient means extravasation is not highly dependent on the
intercapillary spacing as it is for oxygen. What is important is the
surface area of active blood vessels (Figure 2B, bottom). This
tumor section shows intense perivascular staining of an A431
tumor with a fluorescent antibody except for the region in the
lower left. Here a lack of functional blood vessels (no functional
surface area) has limited the local uptake. The capillary wall
barrier also reduces wash-out from the tumor, resulting in non-
specific (size-mediated) enhanced permeability and retention
(EPR) effect [39]. The tumor uptake of class II agents from
antibodies to nanoparticles can be predicted with this type of
modeling [40].
In contrast to the above classes, Class IV agents (e.g. FDG) show
uniform tissue concentrations (Figure 2C, top). To ensure this was
not an artifact of homogeneous consumption, the uptake rate was
arbitrarily given a sinusoidal function in the axial and radial
directions. While the internalized FDG-6-phosphate correlated
with the uptake rate (Figure 2C, bottom), the interstitial
concentration remained constant. This is typical for a class IV
agent; the local binding and metabolism rate determines the probe
uptake. The localization of this probe is therefore dependent on
local glucose consumption, not on delivery. Pugachev et al.
showed that FDG colocalized with hypoxic regions that consume
more glucose rather than perfusion [41]. This is in contrast to
antibodies, where uptake in vitro [42] and in vivo [43] does not
correlate to expression unless saturating doses are used.
Dimensionless Parameters
This systems approach can yield more information than just the
rate-limiting step; dimensional analysis of the differential equations
is also informative. Given the four major steps in localization,
three dimensionless numbers were defined (File S1): the vessel
depletion number, Biot number, and Damkohler number. The
Biot number and Damkohler number have their origins in
differential equations that arise in several fields including heat
transfer and chemical reaction and diffusion [44], but the vessel
depletion number, being more specific to physiological problems,
has only appeared in a few forms (e.g. [45]).
The vessel depletion number is the ratio of extravasation to
blood flow rate. A number greater than one indicates the flow rate
is important, while a number less than one shows low sensitivity to
blood flow. This is defined on both a microscopic scale (velocity
along an individual vessel segment) and a macroscopic scale
(volume averaged rates). Oxygen has a large ratio, resulting in the
decreasing concentration along the axis in Figure 2. This ratio
would be much larger were it not for the significant fraction of
oxygen bound to hemoglobin in the blood. This bound ‘source’ in
the blood helps buffer the loss of oxygen along the length of the
vessel, and highly plasma protein bound drugs also show this
effect. This occurs for drugs like doxorubicin where 75% of the
drug is bound to plasma proteins. FDG has a ratio greater than
one, and this affects the distribution at early times after injection
discussed below. The vessel depletion number for antibodies is well
below unity, and there is no drop in axial concentration.
The Biot number is a ratio of the extravasation rate to diffusion
in the tissue and is useful in relating the plasma concentration to
the tissue concentration. Oxygen equilibrates rapidly across the
endothelium with a Biot number of 5 (with other estimates 30 and
higher [46]), in contrast to the concentration of free antibody in
the tissue, which is approximately 100-fold lower than what is in
the blood. Eventually, bound antibody accumulates to significant
levels and this concentration difference is not as apparent. An
estimate of the concentration difference across the vascular
endothelium during maximum uptake is:
½C interstitium,free
½C plasma,free
&
Bi
Biz1
where [C]interstitium,free is the unbound drug in the tissue interstitial
space, [C]plasma,free is unbound drug in the plasma, and Bi is the
Biot number.
Heterogeneity in the tissue is best captured by the Damkohler
number, the ratio of local binding/reaction versus diffusion in the
tissue. If the ratio is much less than one, such as with FDG (and
oxygen in well vascularized areas), diffusion is faster than
immobilization, and there are few radial gradients in the tissue.
Ratios much larger than one result in rapid immobilization and
large radial gradients, such as with doxorubicin and antibodies. It
is important to note that this heterogeneity is caused by the rapid
binding rate relative to diffusion (often termed the ‘binding site
barrier’ for antibodies [47]), but the rate-limiting step for tumor
uptake is still extravasation for antibodies since they are a class II
agent.
Class Variation
Tumor pharmacokinetics are highly complex, and there are
notable exceptions to the categorical behaviors presented above.
For example, oxygen has been shown to be limited by blood flow
in acute hypoxia scenarios but by diffusion in chronic hypoxia. A
simpler case is in healthy tissue, where oxygen is not limited by any
of these steps but rather tissue metabolism (class IV). The body
strives to maintain the supply by redirecting flow and maintaining
evenly spaced vessels. To increase oxygen uptake in these tissues,
the tissue must simply metabolize (utilize) more oxygen. Oxygen,
and other drugs, can therefore vary depending on spatial
differences (e.g. local vascularization), temporal changes (e.g.
blood flow), and tissue type (healthy versus tumor). Despite these
inherent complexities, this systems analysis provides a logical
framework in which to discuss and understand these variations. A
few informative examples are presented below.
Antibodies are excellent targeting agents with high binding
affinity and specificity, and they are used in the clinic for both
therapy and imaging. As macromolecules, they are class II agents,
limited by permeability and blood vessel surface area in the tumor.
However, with increasing doses, eventually all the binding sites
within the tumor are targeted, and the tumor sites become
saturated. At this point, further uptake is limited by the lack of free
binding sites, not delivery by extravasation. Once saturation has
been reached, the antibody behaves as a binding site limited, or
class IV, agent. This has major implications for antibodies as
imaging agents, since a difference in expression can only be
detected at saturating doses. Several groups have demonstrated
this non-linear behavior [48] and requirement of saturation [3,4].
For a direct example, Figure 3 shows a mouse with HT-29 tumors
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4 EGFR/cell and A431 tumors (right)
expressing 4x10
6 EGFR/cell. Both tumors have similar levels of
vascularization, so a subsaturating 30 mg dose results in similar
uptake between both tumors. The mouse on the right has the same
tumors but was injected with 300 mg of cetuximab, more than
enough to saturate the HT-29 tumor. Here there is a statistically
significant difference between the tumors. The background also
increased given the 10-fold higher dose. This is an important
example where an agent switches from class II behavior to class IV
behavior based on the dose.
Variations in distribution can also occur during the initial
transient phases of drug distribution. The FDG simulation results
in Figure 2C were shown at 1 hr after injection. During the first
few minutes after i.v. administration, the drug has not ‘filled up’
the interstitial space in the tumor, and the metabolic uptake does
not dominate the distribution. Simulation results for the first 12
minutes after FDG administration are shown in Figure 4A. The
concentration along the length of the blood vessel shows steep
axial gradients at early times, and at this point, uptake is limited by
blood flow. Only after the drug has evenly distributed in the tissue
does the heterogeneity vanish. In fact, Mullani et al. have taken
advantage of this transient class I behavior by using the FDG
signal during the first 2 minutes of administration to measure
tumor blood flow [24]. This is in contrast to antibodies (Figure 4B),
which show no axial gradients and uniform plasma concentration.
Experimentally, this is demonstrated with fluorescent vascular
imaging agents [35], which are often macromolecules. The
concept of small molecules as blood flow indicators and
macromolecules as indicators of blood volume is well known in
the MRI community [49].
Although drugs can vary between classes depending on factors
such as time, dose, location, and tissue, the drastically varying
pharmacokinetic parameters often result in drugs lying well within
a particular region (File S1). Even with spatial and temporal
variability, drug pharmacokinetics are often dominated by a single
class per drug.
Multidrug regimen
An unbiased approach is beneficial when studying new agents
where the rate limiting steps and distribution are currently
unknown. However, it is also important for well-studied drugs
when used in multi-drug regimens [6]. In these cases, the agents
often fall into different classes, and the overlap in concentration
between the two drugs is highly variable. For example, oxygen is a
class I agent, being limited by blood flow (with class III diffusion
limitations near necrotic regions). Hypoxic regions are known to
be resistant to radiation and certain types of chemotherapy.
Antibodies, class II agents, are currently being explored as carriers
for radioisotopes and chemotherapy drugs [50]. A full tumor
pharmacokinetic systems analysis shows that these drugs will
deliver radiation and chemotherapy to a range in oxygenation
levels in the tumor (Figure 4C). Similarly, pretargeting strategies
for imaging [51] and therapy [11,52] typically pair a slowly
cleared antibody (class II) with a rapidly cleared small molecule
(class I) secondary agent. Colocalization and binding of these
agents may only occur in regions with sufficient blood flow
(Figure 4D), while antibody in other regions may never be exposed
to secondary agent.
Besides illumination of the challenges, the described approach
can be used to provide guidance for circumventing a given
problem. Judicial use of anti-angiogenic therapies may benefit
certain situations. Therapies such as bevacizumab and other anti-
angiogenic treatments ‘normalize’ tumor blood vessels by reducing
permeability, increasing pericytes coverage, and restoring pressure
gradients [53]. A disruption in this pathological signaling pathway
Figure 3. Class variation with antibodies. Mice with HT-29 tumor on the left side and A431 tumors on the right side were injected with 30 mg
(left) or 300 mg (right) of cetuximab-VT680. The lower dose is subsaturating, so uptake is limited by delivery from the vasculature with similar uptake
in both tumors. At saturating doses, the uptake is limited by the number of binding sites, and uptake is statistically higher in the A431 xenografts,
which express EGFR at a much higher level. The reported p values are from a two-tailed t-test.
doi:10.1371/journal.pone.0024696.g003
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[14]. Based on this systems analysis, this results in contrasting
effects. Class I agents will have synergistic effects with anti-
angiogenic drugs, since this will increase blood flow and delivery
into the tissue [54]. In fact, this is how these drugs are often used
in the clinic [10]. Class II agents, however, are limited by
permeability and will be antagonized by the drug since it is
predicted to decrease their uptake. We speculate that this may
have played a role in the failure of combining antibody treatments
in two recent clinical trials [55,56], but more investigation into this
complex scenario is required.
Discussion
Here we define four fundamental classes of agents for drug
distribution in tumors: those limited by blood flow, vessel
permeability, interstitial diffusion, and local binding and metab-
olism. Identifying the rate-limiting step is important in under-
standing restrictions on total uptake, developing more complex
and specialized pharmacokinetic models, pairing pharmacokinetic
models with pharmacodynamic studies (e.g. PK/PD modeling),
interpreting experimental results, predicting drug overlap and
interactions for multi-drug regimens, and designing novel
molecules for imaging and therapy.
Pharmacokinetic Classes
Blood flow limited agents form the first class of molecules, and
this includes oxygen and many small molecule chemotherapeutics
such as doxorubicin. Pharmaceutical developers may select for
these types of agents when developing orally available drugs.
Agents that are able to passively cross the intestinal lining in the
gut will also be able to passively cross the endothelium in blood
vessels. Biologically, these membranes are very different, and
considerations of transporters and specific interactions require
more specialized models. However, at the fundamental physio-
chemical level, both consist of lipid bilayers and aqueous solutions,
and drugs that quickly and passively cross the intestinal epithelium
may also quickly cross the tumor endothelium.
Class II agents are primarily limited by their permeability across
the endothelium and include biologicals (antibodies) and nano-
materials. Because these agents have difficulty crossing mem-
branes, they are often delivered parenterally, such as by
intravenous infusion or subcutaneous injection. The slow exit
Figure 4. Class variation in time and multi-agent simulations. The plasma profile along the length of the vessel is shown for the first 12
minutes for FDG (A) and an antibody (B). The axial gradients indicate a transient blood flow limitation (class I) for FDG while the antibody evenly fills
the blood volume. (C) A joint simulation of oxygen (color scale) and a monoclonal antibody (z-axis) show differential uptake. The antibody is delivered
to regions not reached by the blood flow limited oxygen, and other regions are well oxygenated with no antibody. (D) Similarly, a pretargeting
simulation with higher antibody dose (z-axis) and reacting secondary agent (color scale) shows some regions targeted by the primary antibody may
be missed by the rapidly cleared and blood flow limited small molecule secondary agent.
doi:10.1371/journal.pone.0024696.g004
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blood flow, so these agents have the potential to access regions of
the tumor with low blood flow.
The mechanistic causes of diffusion-limited uptake are likely the
most poorly characterized in the literature. While several papers
have described diffusion-limited results [9,57], the reasons why
these differ from other similar sized agents has not been well
described. This most often occurs for highly lipophilic agents of
low molecular weight. Interestingly, their extravasation rates and
diffusion rates are typically higher than molecules of similar
molecular weight [58]. Given that these molecules have higher
permeability and diffusion coefficients than similar but more
hydrophilic class I molecules, why are they limited by diffusion?
These model results indicate it is due to their high level of plasma
protein binding that spares these agents from blood flow
limitations. The large fraction of protein bound drug serves as a
depot in the blood that maintains the concentration of free plasma
drug along the length of the blood vessels. The high lipophilicity
allows significant extravasation of free drug, resulting in a class III
agent. Since these drugs penetrate cell membranes, the endothe-
lium is just one of many cell layers the drug must pass. This is in
contrast to macromolecular class II agents, where the large flat
endothelial cells connected by tight junctions form a significant
barrier.
Class IV agents are limited in their uptake by local binding and
metabolism. Of all the classes, this one is the most difficult to
predict. The localization rate is dependent on the specific
mechanism of immobilization in the tissue including binding,
cellular uptake, metabolism, pinocytosis, or enzymatic activation.
Because of this, it is more difficult to generalize the properties of
these agents, and it includes small molecules such as FDG and
macromolecules like protease sensors [35]. Even more complicat-
ed are cases where the result is dose dependent, such as saturating
doses of antibodies and extreme cases of necrosis, where even
FDG can be limited in uptake [59]. However, this class is very
important for developing quantitative imaging agents. Imaging
modalities such as PET, SPECT, and MRI are quantitative in
nature, but the localization of contrast agents is often not. Many
times the localization is dependent on blood flow and/or
permeability, not exclusively on the level of target that is being
measured. This remains a challenge in the field, and predictive
models are very useful in guiding agent design to ensure their
uptake correlates with target levels before engaging in time
consuming and more expensive in vivo validation.
Tumor Heterogeneity
Tumor physiology is extremely complex and heterogeneous,
and the values of blood flow [21,25], vascularization [60], vessel
distribution [61], and target concentration [43,62] vary signifi-
cantly within and between tumors. While drug distribution in
tumors is the result of both tumor specific and drug specific
parameters, the large range in drug properties dominate the
classification. For example, vessel permeability of macromolecules
may vary 10-fold between tumors and normal tissue [26], but the
permeability of oxygen relative to macromolecules spans 5 orders
of magnitude. Only when a drug is borderline between two classes
will tumor heterogeneity have a major impact. For example, an
antibody close to a saturating dose will saturate more highly
vascularized regions prior to less vascularized regions (borderline
between class II and class IV). Tumor heterogeneity has a greater
influence on the distribution within a particle class. For example,
the variability in blood flow to different regions of the tumor will
affect the distribution of class I agents, while the variability in
vessel surface area will cause heterogeneous distribution of class II
agents (e.g. Figure 2b). This heterogeneity between tumor regions
is many times correlated; highly vascularized regions often have
high blood flow rates, a large vessel surface area, and small
diffusion distances between vessels. The opposite is true for semi-
necrotic and necrotic regions.
The different agent properties can be used to rationally design
probes for measuring these variable tumor parameters and any
pharmacologically induced changes. Small tracers with minimal
plasma protein binding (class I) will distribute in regions of high
tumor blood flow, while macromolecules (class II) will initially fill
the blood volume but can be used to measure macromolecular
permeability [49].
Dimensional Analysis
Unbiased analysis of the transport rates also provides insight
into the distribution of agents in the tumor. Dimensional analysis
results in three numbers that describe the distribution: the vessel
depletion number, Biot number, and Damkohler number. The
first provides insight into the importance of blood flow in active
vessels including the impact of transient and variable tumor blood
flow. The Biot number describes the tissue concentration relative
to the plasma concentration, often useful for in vitro/in vivo
correlations. Values much greater than unity indicate equilibrium
is achieved, and the plasma concentration is equal to the tissue
concentration, at least in close proximity to the vessels. However,
for class II agents, this value is often much less than one, and the
free drug concentration just outside the vessel is much less than
that in the blood. Finally, the Damkohler number describes the
rate of immobilization (reaction) to the rate of transport (diffusion).
A value much greater than one results in very heterogeneous
uptake.
Pharmacokinetic Simulations
The described analysis of transport may be particularly useful
when developing more specialized and sophisticated pharmacoki-
netic models for specific agents. The tumor microenvironment is
extremely complex biologically with heterogeneous physiology.
Many of the parameters used in this analysis vary significantly
spatially and temporally in tumors. However, the drug uptake and
distribution is generally not sensitive to all of these variations and
typically is heavily dependent on only a few. This provides an
opportunity for model reduction, where several aspects of
transport can be ignored since the drug uptake has little or no
sensitivity to these parameters. For example, models of antibody
transport often ignore issues of blood flow and the corresponding
axial variations, since the concentration is not depleted along the
length of vessels [38,63]. Even greater model reduction is possible
for FDG. Given the lack of radial and axial gradients,
compartmental models have been successful in describing and
analyzing FDG data, most notably Patlak analysis [18]. This
analysis is also useful for selecting the type of physiologically based
pharmacokinetic (PBPK) model for data fitting. In these models,
each organ is treated as a separate compartment, but given the
large number of parameters, most often the individual rates are fit
from experimental data. The systems analysis describes whether
transport rates are related to blood flow [8] or extravasation [64].
The collection of rates now available in the literature (File S1)
should facilitate the development of more predictive models [65].
Another aspect that enables simplification in Patlak analysis is
the assumption of irreversible uptake. This allows the analysis to
focus simply on uptake, which is correlated with glucose
consumption. While a detailed description of different mechanisms
of clearance is beyond the scope of this paper, we will mention
them briefly. The first mechanism of clearance results from
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biliary excretion) and/or kidney filtration [8]. This reduces the
driving force for uptake and can eventually remove drug from the
tissues if the gradient is reversed. The second mechanism is local
clearance, such as by metabolism in the tissue. A typical example
would be the internalization and degradation of antibodies, which
have very slow plasma clearance [66,67]. A final mechanism of
clearance is radioactive decay, which is often important with
imaging agents. Imaging instrumentation often reports decay-
corrected radioactivity, but the activity must be strong enough for
sufficient signal to noise ratios and reasonable image capture
times. Quickly decaying isotopes such as F-18 require agents that
localize on the same time scale before the radioactivity is ‘cleared.’
Identifying both the rate-limiting step in uptake (class I through
IV) and major mechanism of clearance is informative, since it is
this ratio that determines the maximum uptake in the tumor and
the specific time course of drug concentration.
Conclusions
The factors controlling delivery are extremely complex, and a
theoretical analysis is required to try and parse out logical
principles. With further development of predictive models, the
distribution of drugs will be able to be included in the drug
development process for more efficacious therapies. This is very
important for small molecule drugs, which are difficult to track
with autoradiography. Most small molecule drugs are not
characterized at this level, but doxorubicin provides an exception
due to its intrinsic fluorescence. By using a systems approach to
analyze the pharmacokinetics for imaging agent development,
newer agents can be rationally designed for the purpose at hand,
such as measuring target expression. In silico design paired with
experiments will be an increasingly powerful approach to
developing new agents.
Theoretical analysis of tumor pharmacokinetics can provide
guiding principles for drug and imaging agent design. Often times
experimental results do not agree with the expected outcome, and
a variety of factors are discussed that could be the cause of this
discrepancy. Many times these deviations are driven by only one
or a few of these factors, and this model framework provides the
basis for narrowing down the list of possibilities in determining
these controlling factors. These principles will become even more
important as drug regimens and imaging techniques increase in
complexity. This approach can be used by experimentalists to
qualitatively understand the different delivery issues or quantita-
tively estimate the dimensionless parameters that predict uptake
and distribution. The parameters outlined here and in the
references can be used as a starting point for developing more
sophisticated simulations for the molecule of interest. In this
manner, a systems approach to tumor pharmacokinetics provides
insight into the difficult to measure tumor distribution of drugs and
can help in interpreting experimental data, forming more
sophisticated pharmacokinetic models, and designing newer, more
efficacious imaging agents, drugs, and treatment regimens.
Supporting Information
File S1 Dimensional Analysis with 3D Plot, Model
Equations, Parameterization, and Additional Valida-
tion. The model equations are used to derive the dimensionless
numbers, and the four classes are mapped in three-dimensional
space relative to these three groups. References are provided for
the parameter values used in the model, and additional simulation
results for oxygen and doxorubicin are presented for further model
validation.
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